Trending

Opdivo

BMS pulls Opdivo/Yervoy in first-line lung cancer

BMS pulls Opdivo/Yervoy in first-line lung cancer

Bristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line

X

BMS pulls Opdivo/Yervoy in first-line lung cancer

https://pharmaphorum.com/news/bms-pulls-opdivo-yervoy-in-first-line-lung-cancer/

BMS gets new OK for Opdivo/Yervoy in kidney cancer

BMS gets new OK for Opdivo/Yervoy in kidney cancer

Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green

X

BMS gets new OK for Opdivo/Yervoy in kidney cancer

https://pharmaphorum.com/news/bms-gets-new-ok-for-opdivo-yervoy-in-kidney-cancer/

BMS looks to RNA splicing to boost immunotherapies

BMS looks to RNA splicing to boost immunotherapies

Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and

X

BMS looks to RNA splicing to boost immunotherapies

https://pharmaphorum.com/news/bms-looks-to-rna-splicing-to-boost-immunotherapies/

Merck bags adjuvant okay for Keytruda in melanoma

Merck bags adjuvant okay for Keytruda in melanoma

Checkpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval

X

Merck bags adjuvant okay for Keytruda in melanoma

https://pharmaphorum.com/news/merck-bags-adjuvant-okay-for-keytruda-in-melanoma/

Opdivo and Keytruda approved in new lung cancer uses

Opdivo and Keytruda approved in new lung cancer uses

The FDA has approved Merck’s Keytruda (pembrolizumab) as a combination treatment for metastatic nonsquamous non-small cell lung cancer

X

Opdivo and Keytruda approved in new lung cancer uses

https://pharmaphorum.com/news/bmss-opdivo-approved-lung-cancer/

Merck & Co’s Keytruda shows potential in head and neck cancer use

Merck & Co’s Keytruda shows potential in head and neck cancer use

Merck & Co might be able to find another use for its immunotherapy Keytruda in first line head

X

Merck & Co’s Keytruda shows potential in head and neck cancer use

https://pharmaphorum.com/news/keytruda-shows-promise-first-line-skin-cancer-treatment/

BMS strikes back with lung cancer combo success

BMS strikes back with lung cancer combo success

Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.

X

BMS strikes back with lung cancer combo success

https://pharmaphorum.com/news/bms-strikes-back-lung-cancer-combo-success/

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy

X

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

https://pharmaphorum.com/news/bms-infinity-aim-overcome-triple-negative-breast-cancer-resistance-io/

BMS and Roche look to Halozyme drug delivery for IO advantage

BMS and Roche look to Halozyme drug delivery for IO advantage

Bristol-Myers Squibb is to work with drug delivery specialist Halozyme to create an injectable form of its blockbuster

X

BMS and Roche look to Halozyme drug delivery for IO advantage

https://pharmaphorum.com/news/bms-roche-look-halozyme-drug-delivery-io-advantage/

1 2 3 4

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com